- RNA-based therapy developer Silence Therapeutics said chief financial officer David Ellam had stood down with immediate effect.

Current head of financial planning and analysis, Rob Quinn, would serve as interim CFO while a replacement was found.

'On behalf of the board I would like to thank David for his contribution to Silence,' chief executive David Horn Solomon said.

'He has played an important role in building the business and placing Silence Therapeutics in a strong position to continue the development of its product pipeline in the RNAi medicines space.'

At 8:10am: [LON:SLN] Silence Therapeutics PLC share price was 0p at 53.2p

Story provided by